Previous 10 | Next 10 |
2024-05-24 21:15:02 ET Stephens analyst issues BUY recommendation for GH on May 24, 2024 05:00PM ET. The previous analyst recommendation was Buy. GH was trading at $25.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...
2024-05-24 09:25:08 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health colorectal cancer screening test endorsed by FDA advisors Guardant shares ...
The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood t...
2024-05-23 17:05:39 ET More on Guardant Health Guardant Health slips as FDA comments on cancer screening test Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quan...
2024-05-23 08:39:07 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health slips as FDA comments on cancer screening test Guardant Health Non-GAAP EP...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet to...
2024-05-21 11:05:08 ET More on Guardant Health Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript Guardant Health Non-GAAP EPS o...
Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption of guideline-recommended genomic profiling to inform optimal therapy selection for p...
2024-05-20 16:47:47 ET Gainers: Maravai LifeSciences ( MRVI ) +5% . Caribou Biosciences ( CRBU ) +4% . Greenidge Generation Holdings ( GREE ) +4% . Cipher Mining ( CIFR ) +4% . SIGA Technologies ( SIGA ) +4%...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (C...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test covered by Medicare for comprehensive genomic profiling of all advanced solid tu...
2024-06-04 07:00:06 ET Kyle Mikson from Canaccord Genuity issued a price target of $38.00 for GH on 2024-06-04 05:20:00. The adjusted price target was set to $38.00. At the time of the announcement, GH was trading at $27.41. The overall price target consensus is at $58.2...